Aflibercept 8 mg first to achieve sustained vision gains with more than 70% of patients extended to intervals between 16 and 24 weeks in wet age-related macular degeneration at two years

10

August

2023

|

12:59 PM

Europe/Amsterdam

Not intended for U.S. and UK Media – Two-year topline results from the pivotal study PULSAR:

Summary

Results from PULSAR demonstrate long term efficacy of aflibercept 8 mg with extended dosing intervals reaching up to 24 weeks and vision improvements comparable to Eylea™ (aflibercept 2 mg) at fixed 8-weekly dosing over two years / Patients randomized at baseline to aflibercept 8 mg 16-week dosing regimen received a mean of 8.2 injections (4.6 fewer than Eylea (aflibercept 2 mg)) over two years / Safety profile of aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) remains comparable to Eylea (aflibercept 2 mg) with no new signals identified

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Bayer.com – https://www.bayer.com/media/en-us/aflibercept-8-mg-first-to-achieve-sustained-vision-gains-with-more-than-70-of-patients-extended-to-intervals-between-16-and-24-weeks-in-wet-age-related-macular-degeneration-at-two-years/